NCT02213913 2026-03-11
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
University of Chicago
Phase 1/2 Completed
Clinical Trials
76 trialsNCT06191744 2026-03-03
EPCOREâ„¢FL-2
Genmab
Phase 3 Recruiting
NCT05389423 2026-02-19
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT02356159 2025-09-30
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00278408 2025-08-26
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Universität des Saarlandes
Phase 3 Completed
NCT04546620 2025-08-06
REMoDL-A
University Hospital Southampton NHS Foundation Trust
Phase 2 Active not recruiting
NCT00878254 2025-07-23
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma
University of Miami
Phase 2 Completed
NCT00001379 2025-06-19
Treatment and Natural History Study of Lymphomatoid Granulomatosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01303887 2025-04-18
PACIFICO
University of Liverpool
Phase 3 Completed
NCT05578976 2025-01-23
EPCORE DLBCL-2
Genmab
Phase 3 Active not recruiting
NCT03467373 2025-01-17
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
Hoffmann-La Roche
Phase 1 Completed
NCT02626455 2024-12-11
CHRONOS-4
Bayer
Phase 3 Terminated
NCT02406092 2024-11-21
Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A
Hoffmann-La Roche
Phase 3 Completed
NCT01843868 2024-08-07
Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Australasian Leukaemia and Lymphoma Group
Phase NA Withdrawn
NCT00596154 2024-04-01
PCNSL
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03571308 2023-09-28
ACCEPT
University Hospital Southampton NHS Foundation Trust
Phase 1/2 Completed
NCT00004197 2023-09-07
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
University of Nebraska
Phase 2 Completed
NCT02257242 2023-02-09
BRiM
Brown University
Phase 1 Completed
NCT03899337 2023-01-09
STELLAR
University of Birmingham
Phase 2 Recruiting
NCT03036904 2022-08-24
V+DA-EPOCH-R
Weill Medical College of Cornell University
Phase 1 Completed
NCT01332968 2022-08-11
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Hoffmann-La Roche
Phase 3 Completed
NCT05200312 2022-03-11
ZR2-CHOP
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT00193479 2022-03-03
Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01777152 2021-11-30
ECHELON-2
Seagen Inc.
Phase 3 Completed
NCT00000658 2021-11-03
A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 3 Completed
NCT00000703 2021-11-03
Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members
National Institute of Allergy and Infectious Diseases (NIAID)
Phase NA Completed
NCT00000689 2021-11-02
Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 1 Completed
NCT00299182 2021-09-21
Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00053768 2021-05-18
Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma
Universität des Saarlandes
Phase 3 Completed
NCT00290667 2021-05-18
Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma
Universität des Saarlandes
Phase 2 Completed
NCT00004031 2021-02-02
SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
Phase 3 Completed
NCT02055820 2020-06-11
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL
Hoffmann-La Roche
Phase 1/2 Completed
NCT00088530 2020-02-05
BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)
CTI BioPharma
Phase 3 Completed
NCT01851551 2020-01-03
Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL
Acrotech Biopharma Inc.
Phase 1/2 Completed
NCT02568683 2019-04-17
Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
Gilead Sciences
Phase 1/2 Terminated
NCT02518750 2019-04-03
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT02855359 2019-03-11
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Seagen Inc.
Phase 2 Terminated
NCT01818908 2019-02-15
Trial of DA-EPOCH Regimen for NHL With HLH
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT01200758 2018-11-27
A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma
Hoffmann-La Roche
Phase 3 Completed
NCT00002565 2018-11-14
Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00809341 2018-09-25
R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00877006 2018-02-05
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 3 Completed
NCT01724021 2018-01-23
A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a
Hoffmann-La Roche
Phase 3 Completed
NCT00184002 2017-08-10
Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas
University of Southern California
Phase 2 Completed
NCT00719472 2017-05-15
RATE
Genentech, Inc.
Phase 3 Completed
NCT00323323 2017-01-20
CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT00901069 2016-10-17
Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma
University of Kentucky
Phase 1 Completed
NCT01045889 2016-08-19
HDT-HIV
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 2 Completed
NCT00842114 2016-04-04
LNH-Pro-05
Fundación Leucemia y Linfoma, Spain
Phase 2 Completed
NCT00004039 2015-08-19
Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma
Hoag Memorial Hospital Presbyterian
Phase 2 Withdrawn